Payment overview · 2025
General Payments
$670.89
36 reported records · 12 companies
Healthcare provider profile · identity verified
Amber Dawson, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LAKE CHARLES, LA · NPI 1689018665
Verified facts
What the public records show
CMS Open Payments records show Amber Dawson, MD received $670.89 in general payments during 2025 across 36 reported records.
AstraZeneca Pharmaceuticals LP accounted for 31.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $213.31 | 31.8% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $94.76 | 14.1% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $75.77 | 11.3% | 4 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $63.80 | 9.5% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $51.07 | 7.6% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $46.45 | 6.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $28.93 | 4.3% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $28.65 | 4.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.19 | 3.2% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $17.92 | 2.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $15.34 | 2.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.70 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $670.89 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $126.90 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $124.84 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $75.25 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $63.80 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $58.90 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $51.07 | 5 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $46.45 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $38.06 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.29 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $28.93 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $28.65 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.53 | 1 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $17.92 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $15.34 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.70 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 52 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 93 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 57 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 69 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
52 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
63 | 15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
93 | 23 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
53 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
93 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
57 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
69 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 607 | 182 |
| Amlodipine Besylate | Amlodipine Besylate | 432 | 129 |
| Levothyroxine Sodium | Levothyroxine Sodium | 366 | 100 |
| Gabapentin | Gabapentin | 297 | 73 |
| Pantoprazole Sodium | Pantoprazole Sodium | 251 | 71 |
| Losartan Potassium | Losartan Potassium | 223 | 72 |
| Lisinopril | Lisinopril | 217 | 57 |
| Omeprazole | Omeprazole | 215 | 61 |
| Metformin Hcl | Metformin Hcl | 195 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 176 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 166 | 48 |
| Furosemide | Furosemide | 135 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 132 | 48 |
| Trazodone Hcl | Trazodone Hcl | 121 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 109 | 32 |
| Alprazolam | Alprazolam | 108 | 22 |
| Montelukast Sodium | Montelukast Sodium | 108 | 31 |
| Potassium Chloride | Potassium Chloride | 108 | 29 |
| Carvedilol | Carvedilol | 103 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 101 | 27 |
| Simvastatin | Simvastatin | 101 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 94 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 94 | 35 |
| Jardiance | Empagliflozin | 93 | 23 |
| Sertraline Hcl | Sertraline Hcl | 93 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 80 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 76 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 74 | 21 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 74 | 22 |
| Allopurinol | Allopurinol | 73 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 72 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 69 | 21 |
| Ozempic | Semaglutide | 69 | 18 |
| Meloxicam | Meloxicam | 67 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 65 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 65 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 64 | 15 |
| Pregabalin | Pregabalin | 64 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 63 | 27 |
| Symbicort | Budesonide/Formoterol Fumarate | 63 | 15 |
| Glimepiride | Glimepiride | 61 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 59 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 57 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 57 | 23 |
| Mounjaro | Tirzepatide | 57 | 13 |
| Azithromycin | Azithromycin | 54 | 47 |
| Famotidine | Famotidine | 53 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 53 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 17 |
| Farxiga | Dapagliflozin Propanediol | 52 | 11 |
| Lorazepam | Lorazepam | 51 | suppressed |
| Bupropion Xl | Bupropion Hcl | 50 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 49 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 48 | 15 |
| Xarelto | Rivaroxaban | 48 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 47 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | 12 |
| Synthroid | Levothyroxine Sodium | 47 | suppressed |
| Eliquis | Apixaban | 45 | 15 |
| Ezetimibe | Ezetimibe | 43 | 22 |
| Clonidine Hcl | Clonidine Hcl | 41 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 40 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Methylprednisolone | Methylprednisolone | 36 | 28 |
| Bupropion Hcl | Bupropion Hcl | 35 | suppressed |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Trulicity | Dulaglutide | 34 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 33 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | 14 |
| Promethazine Hcl | Promethazine Hcl | 32 | 11 |
| Chlorthalidone | Chlorthalidone | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Temazepam | Temazepam | 28 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 24 |
| Hydrocortisone | Hydrocortisone | 24 | 12 |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Eszopiclone | Eszopiclone | 21 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Cephalexin | Cephalexin | 18 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 15 |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 14 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 13 |
| Nystatin | Nystatin | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Easy Touch | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $670.89 · 36 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, FARXIGA, FREESTYLE LIBRE 3, IBSRELA, JARDIANCE, MOUNJARO, Ozempic, SHINGRIX, SKYCLARYS, The Cologuard Plus Collection Kit, VOQUEZNA, VRAYLAR, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error